JP2010501498A - 抗ｖｅｇｆ抗体による腫瘍治療 - Google Patents

抗ｖｅｇｆ抗体による腫瘍治療 Download PDF

Info

Publication number
JP2010501498A
JP2010501498A JP2009524943A JP2009524943A JP2010501498A JP 2010501498 A JP2010501498 A JP 2010501498A JP 2009524943 A JP2009524943 A JP 2009524943A JP 2009524943 A JP2009524943 A JP 2009524943A JP 2010501498 A JP2010501498 A JP 2010501498A
Authority
JP
Japan
Prior art keywords
antibody
her2
treatment
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009524943A
Other languages
English (en)
Japanese (ja)
Inventor
フリース，トマス
ハスマン，マックス
ショイアー，ベルナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010501498(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010501498A publication Critical patent/JP2010501498A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2009524943A 2006-08-21 2007-08-17 抗ｖｅｇｆ抗体による腫瘍治療 Pending JP2010501498A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013103182A Division JP2013163687A (ja) 2006-08-21 2013-05-15 抗ｖｅｇｆ抗体による腫瘍治療

Publications (1)

Publication Number Publication Date
JP2010501498A true JP2010501498A (ja) 2010-01-21

Family

ID=37607207

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009524943A Pending JP2010501498A (ja) 2006-08-21 2007-08-17 抗ｖｅｇｆ抗体による腫瘍治療
JP2013103182A Withdrawn JP2013163687A (ja) 2006-08-21 2013-05-15 抗ｖｅｇｆ抗体による腫瘍治療
JP2015160099A Ceased JP2015214582A (ja) 2006-08-21 2015-08-14 抗ｖｅｇｆ抗体による腫瘍治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013103182A Withdrawn JP2013163687A (ja) 2006-08-21 2013-05-15 抗ｖｅｇｆ抗体による腫瘍治療
JP2015160099A Ceased JP2015214582A (ja) 2006-08-21 2015-08-14 抗ｖｅｇｆ抗体による腫瘍治療

Country Status (28)

Country Link
US (6) US20080050385A1 (https=)
EP (2) EP2441472B1 (https=)
JP (3) JP2010501498A (https=)
KR (1) KR101136763B1 (https=)
CN (1) CN101505792B (https=)
AR (1) AR062419A1 (https=)
AU (1) AU2007287794B2 (https=)
BR (1) BRPI0715829A2 (https=)
CA (1) CA2660681A1 (https=)
CL (1) CL2007002404A1 (https=)
CO (1) CO6150193A2 (https=)
CR (1) CR10590A (https=)
DK (1) DK2056874T3 (https=)
ES (2) ES2546066T3 (https=)
IL (2) IL196810A0 (https=)
MA (1) MA30654B1 (https=)
MX (1) MX2009001715A (https=)
MY (1) MY150756A (https=)
NO (1) NO20090450L (https=)
NZ (1) NZ574580A (https=)
PE (1) PE20080911A1 (https=)
PL (1) PL2056874T3 (https=)
RU (1) RU2528884C2 (https=)
SG (1) SG174090A1 (https=)
SI (1) SI2056874T1 (https=)
TW (2) TW200825106A (https=)
WO (1) WO2008022746A1 (https=)
ZA (1) ZA200901200B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013163687A (ja) * 2006-08-21 2013-08-22 F Hoffmann La Roche Ag 抗ｖｅｇｆ抗体による腫瘍治療
JP2015502543A (ja) * 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130056201A (ko) * 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
JP5963005B2 (ja) * 2010-07-19 2016-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
NZ607337A (en) * 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
US11406715B2 (en) 2015-05-30 2022-08-09 Genentech, Inc. Methods of treating HER2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
US20230330094A1 (en) * 2020-09-04 2023-10-19 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006042173A2 (en) * 2004-10-04 2006-04-20 Genentech, Inc. Modulators of hepatocyte growth factor activator

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
TR200101343T2 (tr) 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
SK11002001A3 (sk) 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2003042402A2 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2534055A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
CN101355965A (zh) * 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006042173A2 (en) * 2004-10-04 2006-04-20 Genentech, Inc. Modulators of hepatocyte growth factor activator

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5009012002; ＰＥＧＲＡＭ　Ｍ: ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ　ＡＮＤ　ＴＲＥＡＴＭＥＮＴ Ｖ８８　Ｎ．ＳＵＰＰＬ　１, 2004, Ｐ．Ｓ１２４-Ｓ１２５, ＮＩＪＨＯＦＦ *
JPN5009012005; ＥＰＳＴＥＩＮ　Ｍ: ２５ＴＨ　ＡＮＮＵＡＬ　ＳＡＮ　ＡＮＴＯＮＩＯ　ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＳＹＭＰＯＳＩＵＭ Ｖ．７６　ＳＵＰＰＬ．１, 200212, Ｐ．Ｓ１４３ *
JPN6011060419; Ｓｅｍｉｎａｒｓ　ｉｎ　Ｏｎｃｏｌｏｇｙ，　２００２，　Ｖｏｌ．２９，　Ｎｏ．３，　Ｓｕｐｐｌ．１１，　ｐｐ．２９-３７ *
JPN6011060421; Ｃｌｉｎｉｃａｌ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ，　２００６．０２，　ｐｐ．９０４-９１６ *
JPN6013000984; Ｎａｔｕｒｅ　ｂｉｏｔｅｃｈｎｏｌｏｇｙ，　２００５，　Ｖｏｌ．２３，　Ｎｏ．９，　ｐｐ．１１４７-１１５７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013163687A (ja) * 2006-08-21 2013-08-22 F Hoffmann La Roche Ag 抗ｖｅｇｆ抗体による腫瘍治療
JP2015502543A (ja) * 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー

Also Published As

Publication number Publication date
SG174090A1 (en) 2011-09-29
EP2441472A1 (en) 2012-04-18
JP2013163687A (ja) 2013-08-22
HK1134441A1 (en) 2010-04-30
AR062419A1 (es) 2008-11-05
KR20090032136A (ko) 2009-03-31
BRPI0715829A2 (pt) 2013-07-23
MX2009001715A (es) 2009-02-25
US20150239969A1 (en) 2015-08-27
AU2007287794A1 (en) 2008-02-28
RU2009110102A (ru) 2010-09-27
TW200825106A (en) 2008-06-16
PE20080911A1 (es) 2008-08-15
SI2056874T1 (sl) 2012-12-31
NO20090450L (no) 2009-02-27
IL196810A0 (en) 2011-08-01
US20100285010A1 (en) 2010-11-11
NZ574580A (en) 2011-12-22
EP2441472B1 (en) 2015-06-10
CL2007002404A1 (es) 2008-04-18
ES2546066T3 (es) 2015-09-18
CR10590A (es) 2009-03-20
DK2056874T3 (da) 2012-10-15
CO6150193A2 (es) 2010-04-20
RU2528884C2 (ru) 2014-09-20
AU2007287794B2 (en) 2013-03-28
CN101505792A (zh) 2009-08-12
TW201107346A (en) 2011-03-01
JP2015214582A (ja) 2015-12-03
US20110223159A1 (en) 2011-09-15
CA2660681A1 (en) 2008-02-28
MA30654B1 (fr) 2009-08-03
EP2056874B1 (en) 2012-09-19
IL238045A0 (en) 2015-05-31
ES2392630T3 (es) 2012-12-12
CN101505792B (zh) 2012-10-03
MY150756A (en) 2014-02-28
KR101136763B1 (ko) 2012-04-24
PL2056874T3 (pl) 2013-02-28
US20080050385A1 (en) 2008-02-28
US20180251536A1 (en) 2018-09-06
WO2008022746A1 (en) 2008-02-28
US20130183292A1 (en) 2013-07-18
EP2056874A1 (en) 2009-05-13
ZA200901200B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
AU2007287794B2 (en) Tumor therapy with an anti-VEGF antibody
JP5795463B2 (ja) 血管内皮増殖因子に対する抗体と、２型ヒト上皮成長因子受容体に対する抗体を用いた腫瘍治療
AU2007229008B2 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
HK1134441B (en) Tumor therapy with an anti-vegf antibody

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115